A few studies suggest new agents such as Glucagon-like Peptide-1 (GLP-1) agonists as promising drugs, which have demonstrated significant improvement in histological resolution of NASH [32]. The gene discussed is GCG; the disease is metabolic dysfunction-associated steatohepatitis.